Evidence map›Paper›PMID 37470690›Full record

ArticleAging2023

Combined surface functionalization of MSC membrane and PDA inhibits neurotoxicity induced by Fe

Yang Li, Te Liu, Xiuying Li, Modi Yang, Tianxin Liu, Jindian Bao, Miao Jiang, Lingling Hu, Yuzhuo Wang, Pu Shao and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yang LiScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Te LiuScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Xiuying LiScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Modi YangDepartment of Orthopeadics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Tianxin LiuJilin University School of Public Health, Changchun, Jilin, China.
Jindian BaoJilin University School of Public Health, Changchun, Jilin, China.
Miao JiangJilin University School of Public Health, Changchun, Jilin, China.
Lingling HuJilin University School of Public Health, Changchun, Jilin, China.
Yuzhuo WangDepartment of Orthodontics, School and Hospital of Stomatology, Jilin University, Changchun, Jilin, China.
Pu ShaoScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Jinlan JiangScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Jilin University · CNUnion Hospital · CNYibin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extensive utilization of iron oxide nanoparticles in medical and life science domains has led to a substantial rise in both occupational and public exposure to these particles. The potential toxicity of nanoparticles to living organisms, their impact on the environment, and the associated risks to human health have garnered significant attention and come to be a prominent area in contemporary research. The comprehension of the potential toxicity of nanoparticles has emerged as a crucial concern to safeguard human health and facilitate the secure advancement of nanotechnology. As nanocarriers and targeting agents, the biocompatibility of them determines the use scope and application prospects, meanwhile surface modification becomes an important measure to improve the biocompatibility. Three different types of iron oxide nanoparticles (Fe

Indexed as

MAP Kinase Signaling SystemNanoparticlesAnimalsApoptosisAutophagyHumansMiceapoptosisautophagyFe3O4nanoparticlesstem cell membrane

Identifiers

PMID37470690
PMCPMC10415563
OpenAlexW4384818649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.